Author: Hoang, Timothy N.; Pino, Maria; Boddapati, Arun K.; Viox, Elise G.; Starke, Carly E.; Upadhyay, Amit A.; Gumber, Sanjeev; Nekorchuk, Michael; Busman-Sahay, Kathleen; Strongin, Zachary; Harper, Justin L.; Tharp, Gregory K.; Pellegrini, Kathryn L.; Kirejczyk, Shannon; Zandi, Keivan; Tao, Sijia; Horton, Tristan R.; Beagle, Elizabeth N.; Mahar, Ernestine A.; Lee, Michelle YH.; Cohen, Joyce; Jean, Sherrie M.; Wood, Jennifer S.; Connor-Stroud, Fawn; Stammen, Rachelle L.; Delmas, Olivia M.; Wang, Shelly; Cooney, Kimberly A.; Sayegh, Michael N.; Wang, Lanfang; Filev, Peter D.; Weiskopf, Daniela; Silvestri, Guido; Waggoner, Jesse; Piantadosi, Anne; Kasturi, Sudhir P.; Al-Shakhshir, Hilmi; Ribeiro, Susan P.; Sekaly, Rafick P.; Levit, Rebecca D.; Estes, Jacob D.; Vanderford, Thomas H.; Schinazi, Raymond F.; Bosinger, Steven E.; Paiardini, Mirko
Title: Baricitinib treatment resolves lower airway macrophage inflammation and neutrophil recruitment in SARS-CoV-2-infected rhesus macaques Cord-id: y3dgz5d2 Document date: 2020_11_10
ID: y3dgz5d2
Snippet: SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID-19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type-I IFN antiviral resp
Document: SARS-CoV-2 induced hypercytokinemia and inflammation are critically associated with COVID-19 disease severity. Baricitinib, a clinically approved JAK1/2 inhibitor, is currently being investigated in COVID-19 clinical trials. Here, we investigated the immunologic and virologic efficacy of baricitinib in a rhesus macaque model of SARS-CoV-2 infection. Viral shedding measured from nasal and throat swabs, bronchoalveolar lavages and tissues was not reduced with baricitinib. Type-I IFN antiviral responses and SARS-CoV-2-specific T-cell responses remained similar between the two groups. Animals treated with baricitinib showed reduced inflammation, decreased lung infiltration of inflammatory cells, reduced NETosis activity, and more limited lung pathology. Importantly, baricitinib treated animals had a rapid and remarkably potent suppression of lung macrophages production of cytokines and chemokines responsible for inflammation and neutrophil recruitment. These data support a beneficial role for, and elucidate the immunological mechanisms underlying, the use of baricitinib as a frontline treatment for inflammation induced by SARS-CoV-2 infection.
Search related documents:
Co phrase search for related documents- adaptive innate and low frequency: 1, 2, 3, 4
- adaptive innate and low number: 1, 2, 3, 4
- adaptive innate and low quality: 1
- adaptive innate and lung brain: 1, 2, 3, 4
- adaptive innate and lung parenchyma: 1, 2, 3, 4, 5
- adaptive innate and lung tissue: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
- adaptive innate and lymph node: 1, 2, 3, 4, 5, 6, 7, 8
- adaptive innate and lymphocyte neutrophil: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- low frequency and lung brain: 1
- low frequency and lung pathology: 1
- low frequency and lung tissue: 1, 2
- low frequency and lymph node: 1
- low frequency and lymphocyte neutrophil: 1
- low frequency and macrophage activation: 1
- low number and lung brain: 1
- low number and lung tissue: 1, 2, 3
- low number and lymph node: 1, 2, 3
- low number and lymphocyte neutrophil: 1, 2
- low number and lysis buffer: 1
Co phrase search for related documents, hyperlinks ordered by date